• Oasmia signs agreement with FarmaMondo to commercialize Paclical® in Russia & CIS

Read our Management Stories

XR-17 is Oasmia’s proprietary delivery platform

CEO corner

Get to learn more about Francois Martelet, our CEO

Oasmia Pharmaceutical published its interim report for the second quarter of 2021 on August 19, 2021, at 08.00 am CEST.

The company will hold a conference call and an online presentation on the same day at 10.00 am CEST. The call will be hosted by CEO Francois Martelet and CFO Fredrik Järrsten. The presentation will be in English.

The Share

Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program

Annual Report 2020